Monitor YARTEMLEA prescription trends for Q2 and the EMA decision on TA-TMA approval expected mid-2026. NTAP final rule in August could further boost hospital demand.
Price Chart
Executive Summary
Omeros reported Q1 2026 results with first-ever YARTEMLEA commercial sales of $9.9M net, GAAP net income of $56.1M (vs a $33.5M loss a year ago), and non-GAAP adjusted net loss of $17.1M ($0.24/share) that beat consensus of -$0.28. Revenue slightly missed $10.1M consensus. CMS assigned a J-code effective July 1 and recommended NTAP, signaling improving reimbursement.
Key Financial Metrics
Key Facts
- First YARTEMLEA net sales of $9.9M in Q1 2026 (launched Jan 2026)
- GAAP net income $56.1M vs net loss of $33.5M in Q1 2025
- Non-GAAP adjusted net loss $17.1M ($0.24/share) beat consensus $-0.28
- Revenue $9.9M vs consensus $10.1M (miss of ~2%)
- CMS assigned permanent J-code for YARTEMLEA (effective July 1) and recommended NTAP
- Cash and short-term investments $135.3M at March 31; only $70.8M debt remaining (2029 Notes)
- Repurchased 0.4M shares for $4.2M during Q1
Financial Impact
First commercial YARTEMLEA sales of $9.9M; non-GAAP EPS beat consensus by 14%
Risk Factors
- YARTEMLEA adoption may slow without broader label or EU approval
- Non-GAAP adjusted operations still unprofitable; cash burn continues
- Revenue miss could pressure near-term expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-016718 |
| Document: omer20260403_8k.htm | 0001437749-26-016718 |
| Document: 0001437749-26-016718-index-headers.html | 0001437749-26-016718 |
| Document: 0001437749-26-016718-index.html | 0001437749-26-016718 |
| Document: 0001437749-26-016718.txt | 0001437749-26-016718 |
| 8-K Data (Synthetic) | 0001437749-26-016718 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | Insider Cluster | $18.75 $19.04 | ▲ +1.55% | ▲ +1.44% | $18.30 (−2.40%) |
Aug 28, 2026 5w ago | Insider Cluster | $18.61 $19.43 | ▲ +4.41% | ▲ +4.15% | $18.30 (−1.67%) |
Aug 25, 2026 5w ago | Insider Cluster | $18.22 $20.13 | ▲ +10.48% | ▲ +10.26% | $18.30 (+0.44%) |
Aug 21, 2026 5w ago | Insider Cluster | $19.32 $21.05 | ▲ +8.95% | ▲ +7.64% | $18.30 (−5.28%) |
Jul 20, 2026 10w ago | 8-K | $9.53 $17.19 | ▲ +80.38% | ▲ +77.82% | $18.30 (+92.03%) |
Jul 6, 2026 12w ago | 8-K | $10.34 $11.84 | ▲ +14.51% | ▲ +15.07% | $18.30 (+76.98%) |
Jun 18, 2026 15w ago | 8-K | $10.28 $9.22 | ▼ −10.31% | ▼ −10.84% | $18.30 (+78.02%) |
Jun 11, 2026 16w ago | Institutional Cluster | $10.18 $10.27 | ▲ +0.88% | ▼ −1.01% | $18.30 (+79.76%) |
May 13, 2026 20w ago | 8-K | $13.28 $8.74 | ▼ −34.19% | ▼ −33.33% | $18.30 (+37.80%) |
Mar 31, 2026 26w ago | 8-K | $12.08 $14.56 | ▲ +20.53% | ▲ +10.81% | $18.30 (+51.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access